Interpretation of the findings of a cohort study of bacteremic patients with community-acquired pneumonia [3]

Chest

Volumn 132, Issue 5, 2007, Pages 1715-

  Vardakas, Konstantinos Z ^a   Falagas, Matthew E ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMMUNITY ACQUIRED PNEUMONIA; DISEASE COURSE; DRUG EFFICACY; HEALTH STATUS; HOSPITAL ADMISSION; HUMAN; LETTER; MONOTHERAPY; MORTALITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 36348957784     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-0933     Document Type: Letter

References (5)

1. Metersky ML, Ma A, Houck PM, et al. Antibiotics for bacteremic pneumonia: improved outcomes with macrolides but not with fluoroquinolones. Chest 2007; 131:466-473
2. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy lowers mortality among severely ill patient with pneumococcal bacteremia. Am J Respir Crit Care Med 2004; 170:440-444
3. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-1842
4. Mandel LA, Wunderink RG, Azueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27-S72
5. Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123:1503-1511